Less Ads, More Data, More Tools Register for FREE

Pin to quick picksItaconix Plc Regulatory News (ITX)

Share Price Information for Itaconix Plc (ITX)

Share Price is delayed by 15 minutes
Get Live Data
113.50    0.00 (0.00%)
Bid:
110.00
Ask:
117.00
Spread: 7.00 (6.364%)
Market Cap: £15.31m
ITX Live PriceLast checked at - London Stock Exchange

Intraday Itaconix Plc Share Chart

First Bio-based Polymer Application Agreement

26 Jul 2017 14:00

RNS Number : 1460M
Itaconix PLC
26 July 2017
 

26 July 2017

Itaconix plc ("Itaconix")

AkzoNobel and Itaconix finalize first bio-based polymer application agreement

Itaconix has finalized the first application agreement for bio-based polymers to result from its collaboration with AkzoNobel's Specialty Chemicals business, announced earlier this year. This application agreement involves AkzoNobel's Performance Additives unit developing applications for Itaconix polymers to be used in the coatings and construction industries.

"We are pleased to be announcing the first in a series of agreements to develop these polymers for commercial use," said Peter Nieuwenhuizen, RD&I Director for AkzoNobel's Specialty Chemicals business. "Being able to incorporate polymers made from renewable bio-based raw materials will give a significant sustainability advantage for our customers and also fits closely with our own Planet Possible sustainability agenda of doing more with less."

Under the agreement, Itaconix will contribute its proprietary polymers from itaconic acid, which are obtained from sugars through fermentation. Continued Nieuwenhuizen: "In addition to applications in coatings and construction materials, bio-based polymers have the potential to be used in a range of other everyday essentials, ranging from improving water quality to cleaning and hygiene products." Nieuwenhuizen also pointed out that the collaboration with Itaconix is another example of AkzoNobel's approach to embracing open innovation to help find more sustainable solutions.

Dr. Kevin Matthews, CEO of Itaconix, added: "This is the first commercial step in our joint development agreement to collaborate on delivering valuable solutions to AkzoNobel customers with the novel performance of our polymers. We are excited to further strengthen our relationship with AkzoNobel and look forward to combining their deep application knowledge with our unique chemistries to build key product positions in these large and important markets."

 

Ends

For further information please contact:

Itaconix

+44 (0) 1244 283 500

Kevin Matthews / Rob Cridland

N+1 Singer

+44 (0) 207 496 3000

Richard Lindley / Liz Yong (Corporate Finance)

Nick Owen (Corporate Broking)

Hudson Sandler

Charlie Jack / Emily Dillon +44 (0) 207 796 4133

About Itaconix

Itaconix is developing proprietary active ingredients that meet the performance and price needs of its customers and offers them improved safety and sustainability, thereby helping to deliver on the global sustainability agenda, with particular emphasis on the Personal Care and Homecare markets.

www.itaconix.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTDMGZNLVVGNZG
Date   Source Headline
4th Apr 20177:00 amRNSPreliminary Results Announcement - Replacement
27th Mar 20177:00 amRNSFinal Results
1st Mar 20177:00 amRNSChange of Name to Itaconix plc
10th Feb 20177:00 amRNSHolding(s) in Company
1st Feb 20171:33 pmRNSTotal Voting Rights
27th Jan 201711:53 amRNSJoint development agreement with AkzoNobel
23rd Jan 20177:00 amRNSExclusive Supply & Marketing Agreement with Croda
9th Jan 20177:00 amRNSBlock listing Interim Review
3rd Jan 20177:00 amRNSChange of Adviser
30th Dec 20169:22 amRNSDirectorate Change
2nd Nov 20161:18 pmRNSDivestment of Nicotine Gum Business
14th Oct 20167:00 amRNSDirector/PDMR Shareholding
6th Oct 20167:00 amRNSDirector/PDMR Shareholding
30th Sep 20167:00 amRNSDirector/PDMR Shareholding
22nd Sep 20167:00 amRNSInterim Results
19th Sep 20167:00 amRNSDivestment of Nicotine Gum Business
13th Sep 201611:34 amRNSDirectorate Change
7th Sep 20167:00 amRNSFirst Commercial Sales of Itaconix® CHTT
1st Aug 201611:33 amRNSTotal Voting Rights
15th Jul 20168:04 amRNSHolding(s) in Company
11th Jul 20164:34 pmRNSHolding(s) in Company
11th Jul 20163:35 pmRNSBlock listing Interim Review
8th Jul 201611:55 amRNSResult of General Meeting
8th Jul 20167:00 amRNSSuccessful Application for Accelerated Whitewash
22nd Jun 20164:29 pmRNSPosting of Circular and Notice of General Meeting
21st Jun 20162:24 pmRNSResults of Placing
21st Jun 20167:00 amRNSAcquisition & Placing
20th Jun 20165:31 pmRNSAcquisition & Placing
19th May 20162:33 pmRNSResult of AGM
19th May 20167:00 amRNSAGM Statement
7th Apr 20167:00 amRNSNotice of AGM & Posting of Annual Report
1st Apr 20167:00 amRNSTotal Voting Rights
21st Mar 20167:00 amRNSFinal Results
16th Mar 20167:00 amRNSDirectorate Change
1st Mar 20168:41 amRNSTotal Voting Rights
25th Jan 20167:00 amRNSRenewed & Expanded Contract
11th Jan 20167:00 amRNSBlocklisting Interim Review
30th Nov 20155:21 pmRNSHolding(s) in Company
30th Nov 20157:00 amRNSTotal Voting Rights
30th Oct 201512:30 pmRNSTotal Voting Rights
21st Sep 20157:00 amRNSInterim Results
18th Sep 20157:00 amRNSDirectorate Change
7th Sep 201512:18 pmRNSTotal Voting Rights
2nd Sep 20157:00 amRNSBlocklisting Interim Review
1st Sep 20157:03 amRNSLicence with OCI Alabama LLC
15th Jun 201512:27 pmRNSHolding(s) in Company
3rd Jun 20157:00 amRNSGlobal licence signed with Solvay
20th May 201512:17 pmRNSResult of AGM
15th May 20151:21 pmRNSHolding(s) in Company
15th May 20151:17 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.